pre-seed
Stage
About
Eyegenex develops pharmaceutical therapies targeting glaucoma, non-arteritic anterior ischemic optic neuropathy (NAION), and diabetic retinopathy to prevent vision loss, with drug candidates currently in pre-clinical studies and human trials planned for 2026.
Explore Eyegenex's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.